Stock GRF.P GRIFOLS, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

News Grifols, S.A. BME

Equities

GRF.P

ES0171996095

Market Closed - BME
Other stock markets
 11:35:18 2024-06-25 EDT 		5-day change 1st Jan Change
6.515 EUR -2.62% Intraday chart for Grifols, S.A. -0.76% -38.25%
06-25 European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading MT
06-24 European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading
MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading
MT
Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products
MT
RAAS Blood Products Renews Cooperation Deal With Spain's Grifols
MT
European Equities Close Higher in Tuesday Trading; Euro Area, EU Inflation Rises in May
MT
Grifols Biotest receives FDA approval for innovative Yimmugo immunoglobulin to treat primary immunodeficiencies
AQ
Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for $1.72 Billion
MT
Grifols Completes Shanghai RAAS 20% Stake Sale to Haier
MT
Grifols completes sale of a 20% equity stake in Shanghai RAAS and forges strategic alliance with Haier Group
AQ
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
AQ
Haiyingkang Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. from Grifols, S.A..
CI
Sector Update: Health Care Stocks Retreat Late Afternoon
MT
Grifols' Biotest Gets FDA Approval for Yimmugo
MT
Grifols' Biotest Wins US FDA Approval for Primary Immunodeficiency Treatment
MT
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
AQ
Grifols, S.A. Announces Board and Committee Changes
CI
Information on the resolutions approved at the General Shareholders' Meeting of June 14, 2024
AQ
Solaria shares jump on report of takeover interest
RE
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRF Stock
  4. GRF.P Stock
  5. News Grifols, S.A.